Multifunctional inorganic biomaterials: New weapons targeting osteosarcoma

Wang, Dong; Peng, Yi; Li, Yuezhan; Kpegah, Julius K. S. K.; Chen, Shijie

doi:10.3389/fmolb.2022.1105540

Cited by 4 publications

(2 citation statements)

References 167 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OS originates from osteoid and/or immature bone produced by malignant mesenchymal cells, and thus typically affects children, adolescents, and young adults between the ages of 14-18 [ 1 – 3 ]. OS most commonly occurs in the metaphysis of long bones, with the highest incidence in the distal femur, proximal tibia, and proximal humerus, suggesting a link between rapid bone growth and the risk of tumor formation [ 4 , 5 ]. Owing to its high malignancy rate, early metastasis, easy recurrence, and resistance to therapy, it is characterized by a high mortality rate and poor prognosis [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

“…Owing to its high malignancy rate, early metastasis, easy recurrence, and resistance to therapy, it is characterized by a high mortality rate and poor prognosis [ 6 ]. Currently, the primary treatment for OS consists of extensive surgical resection combined with neoadjuvant or adjuvant multidrug chemotherapy, with radiotherapy and immunotherapy playing increasingly important roles in comprehensive OS treatment [ 5 , 7 ]. Nevertheless, the 5-year overall survival outcome of patients with localized OS remains at approximately 70%, with limited therapeutic progress over the past few decades [ 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

FSP1 is a predictive biomarker of osteosarcoma cells’ susceptibility to ferroptotic cell death and a potential therapeutic target

Panczyszyn,

Saverio,

Monzani

et al. 2024

Cell Death Discov.

View full text Add to dashboard Cite

Human osteosarcoma (OS) is a relatively rare malignancy preferentially affecting long body bones which prognosis is often poor also due to the lack of effective therapies. Clinical management of this cancer basically relies on surgical removal of primary tumor coupled with radio/chemotherapy. Unfortunately, most osteosarcoma cells are resistant to conventional therapy, with the undergoing epithelial-mesenchymal transition (EMT) giving rise to gene expression reprogramming, thus increasing cancer cell invasiveness and metastatic potential. Alternative clinical approaches are thus urgently needed. In this context, the recently described ferroptotic cell death represents an attractive new strategy to efficiently kill cancer cells, since most chemoresistant and mesenchymal-shaped tumors display high susceptibility to pro-ferroptotic compounds. However, cancer cells have also evolved anti-ferroptotic strategies, which somehow sustain their survival upon ferroptosis induction. Indeed, here we show that osteosarcoma cell lines display heterogeneous sensitivity to ferroptosis execution, correlating with the mesenchymal phenotype, which is consistently affected by the expression of the well-known anti-ferroptotic factor ferroptosis suppressor protein 1 (FSP1). Interestingly, inhibiting the activity or expression of FSP1 restores cancer cell sensitivity to ferroptosis. Moreover, we also found that: i) AKRs might also contribute to resistance; ii) NRF2 enhances FSP1 expression upon ferroptosis induction; while iii) p53 contributes to the regulation of FSP1 basal expression in OS cells.In conclusion, FSP1 expression can potentially be used as a valuable predictive marker of OS sensitivity to ferroptosis and as a new potential therapeutic target.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

FSP1 is a predictive biomarker of osteosarcoma cells’ susceptibility to ferroptotic cell death and a potential therapeutic target

Panczyszyn,

Saverio,

Monzani

et al. 2024

Cell Death Discov.

View full text Add to dashboard Cite

show abstract

Comprehensive insights into mechanism of nanotoxicity, assessment methods and regulatory challenges of nanomedicines

Havelikar,

Ghorpade,

Kumar

et al. 2024

Discover Nano

View full text Add to dashboard Cite

ZnO-doped β-TCP ceramic-based scaffold promotes osteogenic and antibacterial activity

Mangaraj,

Priyadarshini,

Swain

et al. 2024

Bioinspired, Biomimetic and Nanobiomaterials

View full text Add to dashboard Cite

β-tricalcium phosphate (β-TCP) scaffold, a synthetic bone graft material, has been explored as a potential solution in the healing of bone deformities due to its acceptable degradation rate and ability to support bone growth. However, these scaffolds have limitations such as poor mechanical properties, to stimulate bone growth, and an increased risk of infection after implantation. To overcome these issues, a new type of biomedical scaffold has been developed that incorporated ZnO particles into β-TCP using wet chemical techniques. The scaffolds were created using sintering to produce porous β-TCP scaffolds with good connectivity. The addition of ZnO as a dopant significantly improved the biophysical properties of the scaffolds, with higher concentrations of ZnO leading to better cell adhesion and proliferation. The scaffolds placed in SBF demonstrated their exceptional ability to promote bone growth and regeneration by developing a bone-like apatite layer on their surfaces. The mechanical and physical properties of the scaffolds were effectively assessed using XRD and SEM analyses. To validate the efficacy of the specimen in preventing microbial growth and promoting bone growth, an MTT test, and gene expression investigation were conducted. ZnO-doped β-TCP scaffolds are envisaged to show enormous potential for use in future bone healing applications.

show abstract

Multifunctional inorganic biomaterials: New weapons targeting osteosarcoma

Cited by 4 publications

References 167 publications

FSP1 is a predictive biomarker of osteosarcoma cells’ susceptibility to ferroptotic cell death and a potential therapeutic target

FSP1 is a predictive biomarker of osteosarcoma cells’ susceptibility to ferroptotic cell death and a potential therapeutic target

Comprehensive insights into mechanism of nanotoxicity, assessment methods and regulatory challenges of nanomedicines

ZnO-doped β-TCP ceramic-based scaffold promotes osteogenic and antibacterial activity

Contact Info

Product

Resources

About